SOURCE: Cytomedix, Inc.

Cytomedix, Inc.

February 03, 2012 08:30 ET

Cytomedix Appoints David E. Jorden as Executive Chairman of the Board

Experienced Financial Executive Strengthens Leadership Team

GAITHERSBURG, MD--(Marketwire - Feb 3, 2012) - Cytomedix, Inc. (OTCBB: CMXI) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that David E. Jorden has been appointed as Executive Chairman of the Company's Board of Directors. Mr. Jorden has served on the Company's Board since September 2008 and will replace Acting Chairman of the Board, James Benson, who will remain on the Company's Board and as its Principal Director.

David Jorden, age 49, has a broad business background in finance and investing. From 2003 to 2008 he was a Vice President with Morgan Stanley's Private Wealth Management group, where he was responsible for equity portfolio management for high net worth individuals. Previously he served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Prior to that, Mr. Jorden was a principal with Fayez Sarofim & Co., a manager of investment portfolios for a wide range of clients including pension plans, foundations, endowments, and individuals. Mr. Jorden has an MBA from Northwestern University's Kellogg School and a BBA from the University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr. Jorden serves on the board of Opexa Therapeutics, Inc., as well as two private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI-safer NSAIDs, and DLush, LLC, a deluxe beverage retail concept.

"Over the past four years, David has played an integral role in Cytomedix' growth and is well-suited to serve as our Executive Chair," said Martin P. Rosendale, Chief Executive Officer of Cytomedix. "David has been intimately involved in determining the Company's strategic direction and has lent his considerable financial experience and business acumen in support of those initiatives. Over the past couple of years, we have been building and expanding our leadership with talented, experienced professionals. The addition of David as our Executive Chair further enhances this dynamic team as he is a proven leader with an impressive track record of enhancing operational and financial results and building shareholder value."

"It is a great privilege to have been asked to serve as Executive Chairman of Cytomedix at this important point in the company's evolution," said Mr. Jorden. "With the successful acquisition of the Angel® System last year and the pending license agreement for the AutoloGel® System with a top 20 global pharmaceutical company, we have successfully executed the first phase in our strategic growth plan. Moving forward, we remain committed to building and expanding on our leadership position in regenerative medicine."

About Cytomedix, Inc.

Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma ("PPP") and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Additional information regarding Cytomedix is available at www.cytomedix.com.

Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, the likelihood of success of completing the contemplated licensing arrangement, viability and effectiveness of the Company's growth and sales approach and overall marketing strategies, competitive landscape, the Company's ability to raise additional capital and to continue as a going concern. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2010, filed with the SEC and other subsequent filings. These filings are available at http://www.sec.gov.

Contact Information

  • Contacts:
    Cytomedix, Inc.
    Martin Rosendale, Chief Executive Officer
    Andrew Maslan, Chief Financial Officer
    David Jorden, Executive Chairman
    (240) 499 2680

    Investor Inquiries
    Anne Marie Fields
    LHA
    afields@lhai.com
    (212) 838-3777

    Bruce Voss
    LHA
    bvoss@lhai.com
    (310) 691-7100
    @LHA_IR_PR